RediNews
ETFs Holding ACHN »    ACHN Historical Stock Prices »
ACHN News Video: Fri, Jun 2, 2017, 1:58 PM — Friday's ETF Movers: XBI, XOP


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Achillion Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. Co. is developing small molecules that will target complement factor D, an essential protein within the amplification loop of the alternative pathway of the complement system. The alternative pathway plays a role in a number of diseases including conditions such as paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. Co. has also granted to Janssen Pharmaceuticals, Inc. worldwide rights to develop and commercialize a portfolio of antiviral drug candidates for the treatment of chronic hepatitis C virus. Self directed investors in Achillion Pharmaceuticals Inc will be interested in keeping up with all Achillion Pharmaceuticals Inc news they can find, both ACHN news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ACHN. At RediNews, we simplify this task by presenting both ACHN news releases originating from Achillion Pharmaceuticals Inc itself, and ACHN news from a variety of media outlets. Visitors can browse this news online and through our ACHN RSS news feed.

ACHN News

ACHN News — Articles, Videos, & Press Releases

Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
Tuesday, December 12, 2017, 4:58 PM — Zacks
Short Interest Moves 18.3% Lower For ACHN
Tuesday, December 12, 2017, 1:54 PM — Market News Video
Revance's Neuromodulator Injection Positive in Phase III
Wednesday, December 6, 2017, 1:10 PM — Zacks
AstraZeneca's COPD Drug Succeeds in Label Expansion Study
Tuesday, December 5, 2017, 8:32 AM — Zacks
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug
Monday, December 4, 2017, 8:03 AM — Zacks
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140
Friday, December 1, 2017, 4:51 PM — Zacks
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%
Wednesday, November 29, 2017, 10:53 AM — Zacks
AstraZeneca Files for Label Expansion of Tagrisso in Japan
Tuesday, November 28, 2017, 8:32 AM — Zacks
Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
Thursday, November 23, 2017, 8:12 AM — Zacks
Puma Inks License Deal to Commercialize Cancer Drug Nerlynx
Thursday, November 23, 2017, 7:42 AM — Zacks
Agios Posts New Data on Glioma Candidate from Dose Expansion
Monday, November 20, 2017, 2:42 PM — Zacks
First Week of June 2018 Options Trading For Achillion Pharmaceuticals (ACHN)
Thursday, November 16, 2017, 10:33 AM — Stock Options Channel
Notable Wednesday Option Activity: NGVC, ACHN, SQ
Wednesday, November 15, 2017, 3:26 PM — Stock Options Channel
Achillion (ACHN) Shares Down as J&J Announces Stake Sale
Wednesday, November 15, 2017, 12:30 PM — Zacks
Cardinal Health (CAH) to Divest Assets to Shanghai Pharma
Wednesday, November 15, 2017, 5:36 AM — Zacks
Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin
Tuesday, November 14, 2017, 3:53 PM — Zacks
Glaxo's Subcutaneous Formulation of Benlysta Approved in EU
Tuesday, November 14, 2017, 8:48 AM — Zacks
Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus
Friday, November 3, 2017, 10:08 AM — Zacks
Commit To Buy Achillion Pharmaceuticals At $3, Earn 12.9% Annualized Using Options
Thursday, October 26, 2017, 11:30 AM — Stock Options Channel
Notable Monday Option Activity: PII, ACHN, WFT
Monday, October 23, 2017, 3:22 PM — Stock Options Channel
Achillion's HCV Partnership with J&J Terminated, Stock Falls
Tuesday, September 12, 2017, 9:39 AM — Zacks
How The Parts Add Up: XBI Headed For $103
Thursday, August 24, 2017, 8:39 AM — ETF Channel
Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
Wednesday, August 9, 2017, 8:51 AM — Zacks
Noteworthy Monday Option Activity: ACHN, FEYE, UCTT
Monday, July 31, 2017, 3:26 PM — Stock Options Channel
March 2018 Options Now Available For Achillion Pharmaceuticals (ACHN)
Monday, July 24, 2017, 11:39 AM — Stock Options Channel
Notable Friday Option Activity: HA, PBH, ACHN
Friday, June 2, 2017, 3:32 PM — Stock Options Channel
The Math Shows PXSG Can Go To $33
Tuesday, May 30, 2017, 8:32 AM — ETF Channel
Interesting ACHN Put And Call Options For July 21st
Thursday, May 25, 2017, 10:49 AM — Stock Options Channel
Achillion (ACHN) Reports Wider-than-Expected Loss in Q1
Monday, May 8, 2017, 12:01 PM — Zacks
Interesting ACHN Put And Call Options For December 15th
Tuesday, April 25, 2017, 11:17 AM — Stock Options Channel
Peek Under The Hood: VHT Has 11% Upside
Tuesday, April 25, 2017, 9:37 AM — ETF Channel
Look Under The Hood: VBK Has 10% Upside
Wednesday, March 22, 2017, 8:31 AM — ETF Channel
Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
Tuesday, March 7, 2017, 8:32 AM — Zacks
Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
Wednesday, March 1, 2017, 4:42 PM — Zacks
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
Monday, February 27, 2017, 7:23 AM — Zacks
Will Insiders Be Tempted To Buy More ACHN At The New 52-Week Low?
Friday, February 24, 2017, 2:06 PM — Market News Video
Analysts Anticipate PXSG Will Reach $31
Friday, February 17, 2017, 9:24 AM — ETF Channel
Notable Wednesday Option Activity: ACHN, RH, AJRD
Wednesday, January 25, 2017, 3:33 PM — Stock Options Channel
Commit To Buy Achillion Pharmaceuticals At $3, Earn 13.5% Annualized Using Options
Monday, January 23, 2017, 11:49 AM — Stock Options Channel
J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
Monday, January 23, 2017, 9:15 AM — Zacks
Achillion Receives $15M from J&J for HCV Study Enrolment
Thursday, December 29, 2016, 7:05 AM — Zacks
The Implied Analyst 12-Month Target For BIB
Friday, December 16, 2016, 9:06 AM — ETF Channel
Achillion, J&J to Initiate Phase IIb Study on HCV Combo
Thursday, December 1, 2016, 9:20 AM — Zacks
The Implied Analyst 12-Month Target For PXSG
Tuesday, November 15, 2016, 9:23 AM — ETF Channel
Achillion (ACHN) Reports Narrower-Than-Expected Q3 Loss
Monday, November 7, 2016, 7:29 AM — Zacks
Achillion Pharmaceuticals Becomes Oversold (ACHN)
Friday, October 28, 2016, 1:24 PM — Dividend Channel
First Week of ACHN June 2017 Options Trading
Tuesday, October 25, 2016, 10:51 AM — Stock Options Channel
Will Amgen (AMGN) Sustain its Earnings Beat Trend in Q3?
Friday, October 21, 2016, 8:47 AM — Zacks
Baxter International (BAX) Q3 Earnings: Beat in the Cards?
Friday, October 21, 2016, 8:29 AM — Zacks
Will Medidata (MDSO) Continue to Surprise in Q3 Earnings?
Thursday, October 20, 2016, 8:20 AM — Zacks
What's in Store for Boston Scientific's (BSX) Q3 Earnings?
Thursday, October 20, 2016, 5:51 AM — Zacks
Can Icon (ICLR) Sustain its Surprise Streak in Q3 Earnings?
Tuesday, October 18, 2016, 7:39 AM — Zacks
St. Jude Medical (STJ) Q3 Earnings: What's in the Cards?
Monday, October 17, 2016, 7:19 AM — Zacks
Will These 5 Drug Stocks Be Big Winners This Earnings Season?
Thursday, October 13, 2016, 7:46 AM — Zacks
Bayer (BAYRY) Closes Registration Process for Kyleena in EU
Wednesday, October 5, 2016, 8:15 AM — Zacks
Sarepta/Summit Ink Deal for Utrophin Modulator DMD Drugs
Wednesday, October 5, 2016, 8:06 AM — Zacks
Ocera Therapeutics (OCRX) Jumps: Stock Moves Up 8.5%
Wednesday, October 5, 2016, 6:15 AM — Zacks
Biotech Mergers Run the Show: 5 Small-Cap Stocks for Q4
Tuesday, October 4, 2016, 11:53 AM — Zacks
Roche Alecensa Wins Second Breakthrough Status in the U.S.
Tuesday, October 4, 2016, 8:05 AM — Zacks
Amgen Announces Publication of Blincyto Phase I/II Data
Tuesday, October 4, 2016, 7:53 AM — Zacks
Jazz Initiates Rolling NDA for Leukemia Candidate Vyxeos
Tuesday, October 4, 2016, 7:12 AM — Zacks
New Strong Buy Stocks for October 4th
Tuesday, October 4, 2016, 6:26 AM — Zacks
Achillion, J&J HCV Triple Combination Drug Data Presented
Monday, September 26, 2016, 7:00 AM — Zacks
ACHN Makes Bullish Cross Above Critical Moving Average
Thursday, September 22, 2016, 1:06 PM — Market News Video
Interesting ACHN Put And Call Options For November 18th
Tuesday, September 20, 2016, 10:52 AM — Stock Options Channel
Achillion, J&J's HCV Combo Drug Positive in Phase IIa Trial
Monday, September 12, 2016, 6:43 AM — Zacks
Notable Tuesday Option Activity: ACHN, WEX, VMW
Tuesday, September 6, 2016, 3:39 PM — Stock Options Channel
ACHN March 2017 Options Begin Trading
Monday, July 18, 2016, 11:23 AM — Stock Options Channel
ACHN August 26th Options Begin Trading
Thursday, July 7, 2016, 10:56 AM — Stock Options Channel
Notable Two Hundred Day Moving Average Cross - ACHN
Friday, June 24, 2016, 1:39 PM — Market News Video
Interesting ACHN Put And Call Options For August 5th
Thursday, June 23, 2016, 10:54 AM — Stock Options Channel
First Week of August 19th Options Trading For Achillion Pharmaceuticals (ACHN)
Tuesday, June 21, 2016, 10:49 AM — Stock Options Channel
Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Tuesday, April 26, 2016, 6:02 AM — Zacks
First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
Tuesday, April 19, 2016, 10:42 AM — Stock Options Channel
Interesting ACHN Put And Call Options For May 20th
Tuesday, March 22, 2016, 11:13 AM — Stock Options Channel
Is Horizon (HZNP) Set to Disappoint this Earnings Season?
Friday, February 26, 2016, 1:40 PM — Zacks
Can Endo (ENDP) Keep the Earnings Streak Alive in Q4?
Friday, February 26, 2016, 1:10 PM — Zacks
What's in Store for Exelixis (EXEL) this Earnings Season?
Thursday, February 25, 2016, 1:15 PM — Zacks
Medtronic (MDT) to Report Q3 Earnings: What's in the Cards?
Thursday, February 25, 2016, 1:10 PM — Zacks
Will Atmel's (ATML) Q4 Earnings Disappoint Investors?
Wednesday, February 24, 2016, 12:30 PM — Zacks
What's in Store for Agenus (AGEN) This Earnings Season?
Tuesday, February 23, 2016, 5:09 PM — Zacks
Will Radius Health (RDUS) Disappoint Earnings Estimates in Q4?
Tuesday, February 23, 2016, 3:18 PM — Zacks
BioMarin (BMRN) to Report Q4 Earnings: What's in Store?
Tuesday, February 23, 2016, 1:50 PM — Zacks
Geron (GERN) to Report Q4 Earnings: What's in Store?
Tuesday, February 23, 2016, 1:40 PM — Zacks
What's in Store for Aegerion (AEGR) this Earnings Season?
Monday, February 22, 2016, 3:25 PM — Zacks
Can Keryx (KERX) Surprise Investors this Earnings Season?
Monday, February 22, 2016, 2:40 PM — Zacks
What's in Store for Intercept (ICPT) This Earnings Season?
Friday, February 19, 2016, 4:00 PM — Zacks
Will Allergan (AGN) Continue with its Earnings Streak in Q4?
Friday, February 19, 2016, 1:00 PM — Zacks
Agios (AGIO) Q4 Earnings Preview: Will it Disappoint Again?
Tuesday, February 16, 2016, 11:50 AM — Zacks
Achillion Begins Study on First Complement Factor D Inhibitor
Friday, February 12, 2016, 2:00 PM — Zacks
Achillion Pharmaceuticals is Now Oversold (ACHN)
Friday, February 5, 2016, 4:42 PM — Dividend Channel
A Company's First Profit Can Mean Big Profits to Investors
Tuesday, January 26, 2016, 2:04 PM — Zacks
First Week of ACHN September 16th Options Trading
Friday, January 22, 2016, 12:15 PM — Stock Options Channel
Achillion Pharmaceuticals is Now Oversold (ACHN)
Monday, January 11, 2016, 4:40 PM — Dividend Channel
Commit To Purchase Achillion Pharmaceuticals At $5, Earn 12% Using Options
Monday, January 11, 2016, 4:29 PM — Stock Options Channel
5 Biotech Stocks Ready to Crush the Market in 2016
Monday, January 11, 2016, 12:03 PM — Zacks
Bristol-Myers (BMY) Collaborates with Dual Therapeutics
Monday, January 11, 2016, 9:10 AM — Zacks
Alkermes Upgraded to Hold on Encouraging Portfolio Update
Monday, January 4, 2016, 1:45 PM — Zacks
Dr. Reddy's (RDY) Relaunches Generic Nexium in the U.S.
Thursday, December 31, 2015, 12:50 PM — Zacks
Achillion (ACHN): Moving Average Crossover Alert
Thursday, December 31, 2015, 8:04 AM — Zacks
Discovery Laboratories Advances Respiratory Disease Drug
Wednesday, December 30, 2015, 3:55 PM — Zacks
Mylan Launches its Generic Version of Pfizer's Zyvox
Wednesday, December 30, 2015, 3:40 PM — Zacks
Sarepta's DMD Drug Eteplirsen to Face FDA Panel in January
Wednesday, December 30, 2015, 3:25 PM — Zacks
Anika (ANIK) Starts Enrolment in Phase III HyaloFast Study
Wednesday, December 30, 2015, 1:30 PM — Zacks
Kamada (KMDA) Reports Encouraging Data on Rabies Drug
Tuesday, December 29, 2015, 3:40 PM — Zacks
Sanofi's Dengue Vaccine Dengvaxia Gains Brazilian Approval
Tuesday, December 29, 2015, 3:25 PM — Zacks
Epizyme's Tazemetostat IND Application Accepted for DLBCL
Tuesday, December 29, 2015, 10:40 AM — Zacks
Chimerix (CMRX) Tanks on Disappointing Brincidofovir Data
Tuesday, December 29, 2015, 10:30 AM — Zacks
Eagle's (EGRX) Non-Alcoholic Docetaxel Gets FDA Approval
Monday, December 28, 2015, 3:55 PM — Zacks
Takeda, Teva Reveal Outlook of Japanese Business Venture
Monday, December 28, 2015, 3:45 PM — Zacks
GW Pharmaceuticals Publishes Encouraging Epidiolex Data
Monday, December 28, 2015, 3:35 PM — Zacks
Sanofi Seeks FDA Approval for Diabetes Drug Combination
Monday, December 28, 2015, 3:30 PM — Zacks
Agenus Acquires PhosImmune, Adds Cancer Neoantigens
Monday, December 28, 2015, 2:00 PM — Zacks
Adamas (ADMS) Surges on Positive Data on Lead Candidate
Thursday, December 24, 2015, 1:00 PM — Zacks
Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Wednesday, December 23, 2015, 3:30 PM — Zacks
AstraZeneca's Zurampic FDA Approved with Boxed Warning
Wednesday, December 23, 2015, 3:25 PM — Zacks
Celyad's C-Cure IND Authorized in U.S. for Phase III Study
Wednesday, December 23, 2015, 3:10 PM — Zacks
Celgene (CELG) Settles Revlimid Patent Litigation with Natco
Wednesday, December 23, 2015, 3:00 PM — Zacks
Actelion's Uptravi Approved in the U.S. for PAH Treatment
Wednesday, December 23, 2015, 2:55 PM — Zacks
Baxalta's Adynovate Positive in Phase III Pediatric Study
Tuesday, December 22, 2015, 3:45 PM — Zacks
AVEO Licenses Tivozanib European Rights to EUSA Pharma
Tuesday, December 22, 2015, 3:30 PM — Zacks
Repros Provides Update on Proellex Program, Data by 3Q16
Tuesday, December 22, 2015, 3:25 PM — Zacks
Aduro Doses First Patient in Phase I Study on ADU-741
Tuesday, December 22, 2015, 2:40 PM — Zacks
Applied Genetic Technologies (AGTC) in Focus: Stock Rises 8.5%
Tuesday, December 22, 2015, 7:56 AM — Zacks
Flex Pharma (FLKS) Looks Good: Stock Adds 5.9% in Session
Tuesday, December 22, 2015, 7:40 AM — Zacks
AstraZeneca Updates on Durvalumab; CHMP Favors 3 Drugs
Monday, December 21, 2015, 3:30 PM — Zacks
BioMarin's (BMRN) Kyndrisa Review Period Extended by FDA
Monday, December 21, 2015, 3:20 PM — Zacks
Bristol-Myers Inks Deal to Sell HIV Pipeline to ViiV Healthcare
Monday, December 21, 2015, 3:15 PM — Zacks
Strength Seen in Sequenom (SQNM): Stock Jumps 5% in Session
Monday, December 21, 2015, 7:35 AM — Zacks
Gilead (GILD) Collaborates with Galapagos for Filgotinib
Friday, December 18, 2015, 3:40 PM — Zacks
Alnylam Initiates Final Part of Phase I/II Study on ALN-CC5
Friday, December 18, 2015, 3:30 PM — Zacks
Zoetis (ZTS) Declares 14.5% Hike in Quarterly Dividend
Thursday, December 17, 2015, 1:10 PM — Zacks
AstraZeneca Invests in China, To Buy Respiratory Business
Thursday, December 17, 2015, 11:40 AM — Zacks
Aduro BioTech (ADRO) Looks Good: Stock Moves 8% Higher
Thursday, December 17, 2015, 7:40 AM — Zacks
Clovis (CLVS) Rociletinib's Review Period Extended by FDA
Wednesday, December 16, 2015, 3:40 PM — Zacks
Bristol-Myers/Neon Therapeutics Ink Immuno-Oncology Deal
Wednesday, December 16, 2015, 3:30 PM — Zacks
Amgen Returns More to Shareholders, Hikes Dividend by 27%
Wednesday, December 16, 2015, 1:40 PM — Zacks
Sanofi, Boehringer Ingelheim in Talks over Business Swap
Wednesday, December 16, 2015, 12:55 PM — Zacks
Evotec/Spero Deal Extended For Gram-negative Bacteria
Wednesday, December 16, 2015, 12:20 PM — Zacks
Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session
Wednesday, December 16, 2015, 7:20 AM — Zacks
Akebia Up on Mitsubishi Tanabe Pharma Deal for Vadadustat
Tuesday, December 15, 2015, 3:35 PM — Zacks
Aduro's CRS-207/GVAX Pancreas Gets Orphan Status in EU
Tuesday, December 15, 2015, 3:20 PM — Zacks
Atara Plunges on Poor Results from Phase II PINTA 745 Study
Tuesday, December 15, 2015, 3:10 PM — Zacks
Amgen Regains Rights to Prolia, Xgeva & Vectibix from Glaxo
Tuesday, December 15, 2015, 2:20 PM — Zacks
AstraZeneca Confirms Acquisition Talks with Acerta Pharma
Tuesday, December 15, 2015, 1:20 PM — Zacks
5 Strong Growth Stocks to Buy on Recent Market Dip
Tuesday, December 15, 2015, 12:25 PM — Zacks
Roche's Alecensa Approved in the U.S. for Lung Cancer
Monday, December 14, 2015, 3:55 PM — Zacks
Isis/Biogen Initiate Amyotrophic Lateral Sclerosis Study
Monday, December 14, 2015, 3:35 PM — Zacks
Otonomy's Ear Infection Drug Otiprio Approved in the U.S.
Monday, December 14, 2015, 3:05 PM — Zacks
ARIAD Lowers Iclusig's 2015 Revenue Outlook, Shares Fall
Monday, December 14, 2015, 1:40 PM — Zacks
ACHN Makes Notable Cross Below Critical Moving Average
Monday, December 14, 2015, 11:51 AM — Market News Video
Merck and Eli Lilly Expand Immuno-Oncology Collaboration
Friday, December 11, 2015, 3:55 PM — Zacks
Raptor Reports Efficacy Data from CYST-HD Study on RP103
Friday, December 11, 2015, 3:20 PM — Zacks
Puma (PBYI) Reports Data on Breast Cancer Drug PB272
Friday, December 11, 2015, 1:50 PM — Zacks
Sanofi's Dengue Vaccine Dengvaxia Gets Mexican Approval
Thursday, December 10, 2015, 3:10 PM — Zacks
OncoGenex to Continue with Borealis-2 Study on Apatorsen
Thursday, December 10, 2015, 3:00 PM — Zacks
Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Thursday, December 10, 2015, 2:20 PM — Zacks
Baxalta's Vonvendi Gets FDA Nod for Von Willebrand Disease
Wednesday, December 9, 2015, 3:35 PM — Zacks
Why Achillion Pharmaceuticals (ACHN) Could Shock the Market Soon
Wednesday, December 9, 2015, 7:31 AM — Zacks
Kite Pharma Begins Study on KTE-C19, Presents Data at ASH
Tuesday, December 8, 2015, 3:50 PM — Zacks
Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 13.7%
Tuesday, December 8, 2015, 7:20 AM — Zacks
Amgen Seeks Kyprolis Label Expansion, Inks Deals with Merck
Monday, December 7, 2015, 3:30 PM — Zacks
Eli Lilly Halts Development of Basal Insulin Peglispro
Monday, December 7, 2015, 3:25 PM — Zacks
Stocking Stuffers: 5 Best Stocks Under $20
Monday, December 7, 2015, 2:48 PM — Zacks
Affymetrix (AFFX) Inks Partnership with Reveal Biosciences
Monday, December 7, 2015, 12:10 PM — Zacks
Bluebird Bio Crashes After Clinical Trial Update
Monday, December 7, 2015, 11:29 AM — Zacks
Strength Seen in Sinovac Biotech (SVA): Stock Jumps 8.4%
Monday, December 7, 2015, 7:40 AM — Zacks
Progenics (PGNX) Reaches Target Enrolment in Azedra Study
Friday, December 4, 2015, 2:35 PM — Zacks
KaloBios' Upswing Continues Thanks to Private Placement
Friday, December 4, 2015, 8:50 AM — Zacks
Cytori Reports Positive Top-Line Data on ECCS-50 Yet Again
Thursday, December 3, 2015, 3:39 PM — Zacks
Glaxo's Nucala Receives EU Approval, Launched in the U.S.
Thursday, December 3, 2015, 3:15 PM — Zacks
Baxalta Wins CHMP Backing for Sanquin to Start Production
Thursday, December 3, 2015, 2:35 PM — Zacks
Zafgen Sinks on 2nd Death in Obesity Study, Full Clinical Hold
Thursday, December 3, 2015, 1:40 PM — Zacks
XOMA Inks Agreement with Novo Nordisk for XMetA Program
Wednesday, December 2, 2015, 4:05 PM — Zacks
Celyad Starts 2nd Cohort of Phase I on NKG2D CAR T-Cell
Wednesday, December 2, 2015, 3:55 PM — Zacks
Repros Hits 52-Week Low after Enclomiphene Receives CRL
Wednesday, December 2, 2015, 3:25 PM — Zacks
AbbVie/Bristol-Myers Multiple Myeloma Drug Gets FDA Nod
Tuesday, December 1, 2015, 4:05 PM — Zacks
Ironwood/Astellas Report Positive Phase III Data on Linzess
Tuesday, December 1, 2015, 3:55 PM — Zacks
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Tuesday, December 1, 2015, 3:32 PM — Zacks
Teva Partners with Takeda to Provide Generics in Japan
Tuesday, December 1, 2015, 3:30 PM — Zacks
Ocular Begins Second Phase III Allergic Conjunctivitis Study
Thursday, November 26, 2015, 12:40 PM — Zacks
Eli Lilly's Portrazza Gets FDA Nod, Carries Boxed Warning
Wednesday, November 25, 2015, 2:35 PM — Zacks
AstraZeneca to Divest Entocort U.S. Rights to Perrigo
Tuesday, November 24, 2015, 2:30 PM — Zacks
AMAG Responds to FDA's CRL for Single-Dose Vial of Makena
Tuesday, November 24, 2015, 12:10 PM — Zacks
BioMarin's Vimizim Gets NICE Recommendation in England
Tuesday, November 24, 2015, 11:50 AM — Zacks
Celldex Therapeutics (CLDX) in Focus: Stock Rises 11.9%
Tuesday, November 24, 2015, 7:20 AM — Zacks
AstraZeneca, Sanofi to Swap 210,000 Chemical Compounds
Monday, November 23, 2015, 3:40 PM — Zacks
Celldex Jumps on Phase II Overall Survival Data on Rintega
Monday, November 23, 2015, 3:20 PM — Zacks
SurModics Buys Balloon Catheter Maker Creagh Medical
Monday, November 23, 2015, 3:05 PM — Zacks
BioMarin Down on FDA's Briefing Document on Kyndrisa
Monday, November 23, 2015, 11:40 AM — Zacks
ACHN is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

CHE News
AMSG News
ARTC News
VAR News
PMC News
EBS News
A News
HMSY News
SGYP News
MTD News

RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ACHN News | www.RediNews.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.